Terence P. Gade, MD PhD

Assistant Professor of Radiology
Penn Image-Guided Interventions (PIGI) Lab, Hospital of the University of Pennsylvania

Presentation(s):

• Primary Liver Tumors: Genomic and molecular biomarkers for HCC and Cholangiocarcinoma

  Sunday, March 5, 2023
  9:10 AM – 9:20 AM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Ablation 1

  Sunday, March 5, 2023
  3:00 PM – 4:30 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Genetically Determined Metabotype Renders β-catenin Mutant Hepatocellular Carcinomas Susceptible to Treatment Induced Ischemia

  Monday, March 6, 2023
  12:00 PM – 1:00 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Changes in the Match: Results of an IR Applicant and Program Director Survey Regarding Virtual Interviews and Step 1 Pass/Fail

  Monday, March 6, 2023
  3:00 PM – 3:10 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Integrated IR Residency: Perspectives of Applicants and Program Directors from the 2022 Match

  Monday, March 6, 2023
  3:10 PM – 3:20 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Transarterial Embolization with Hydrogel Embolic System Demonstrates Improved Efficacy as Compared to Particle Embolic in a Translational Rat Model of Hepatocellular Carcinoma

  Monday, March 6, 2023
  3:00 PM – 3:09 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Development and characterization of patient-derived rat models of hepatocellular carcinoma for interventional oncology

  Monday, March 6, 2023
  4:21 PM – 4:30 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Cryoablation of subcutaneous desmoid neoplasms

  Monday, March 6, 2023
  5:05 PM – 5:10 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Intercostal Nerve Block and Neurolysis, Tips and Tricks

  Monday, March 6, 2023
  5:25 PM – 5:30 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• The Growth of IR in the VA: Demonstrating the Value of IR in an Integrated Health Care System

  Tuesday, March 7, 2023
  5:00 PM – 6:00 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Ongoing IO Clinical Trials, Scientific Breakthroughs, and Future Opportunities: An Update

  Wednesday, March 8, 2023
  3:00 PM – 4:30 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• High-Throughput Drug Screening of Patient-Derived Cell Lines Identifies Novel Potential Treatment Options for Hepatocellular Carcinoma

  Wednesday, March 8, 2023
  3:45 PM – 3:54 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)

• Retrospective Review of Non-Infectious Port Complications Leading to Port Removal

  Wednesday, March 8, 2023
  4:21 PM – 4:30 PM

  Disclosure(s): Astra Zeneca: Advisory Committee or Review Panel Member (Terminated); Instylla, Inc.: Research Grant Recipient (Ongoing); Trisalus Life Sciences: Advisory Committee or Review Panel Member (Ongoing)